Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
This study has been completed.
Study NCT00064025 Information provided by National Cancer Institute (NCI)
First Received on July 8, 2003. Last Updated on September 16, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Endometrial Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Adenoma
Carcinoma, Endometrioid
Endometrial Neoplasms
More general conditions related to this trial
Adnexal Diseases
Carcinoma
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Ovarian Neoplasms
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
medroxyprogesterone
microarray analysis
conventional surgery
neoadjuvant therapy
Additional drug interventions recognized in this trial
Medroxyprogesterone Acetate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Gynecologic Oncology Group
National Cancer Institute (NCI)
Back to top of Main Content
